QT Imaging Clears FDA Inspection with Zero Observations — QT Imaging Holdings, Inc.

Event summary

QT Imaging completed its first routine FDA inspection on July 7, 2026 with zero Form 483 observations.
The inspection reviewed the company's Quality Management System and related processes.
FDA inspector provided positive feedback on the organization of QT Imaging’s QMS and the company’s responsiveness during the inspection.
Steve Choate, Chief Operating Officer of QT Imaging, highlighted this as a significant operational achievement.

The big picture

QT Imaging's successful FDA inspection underscores its commitment to quality and regulatory compliance, a critical factor for medical device companies aiming to scale. This achievement positions the company favorably amid increasing competition in the medical imaging sector, where safety, affordability, and accessibility are key differentiators.

What we're watching

Regulatory Compliance: How QT Imaging will maintain its high standards of quality and regulatory compliance as it scales manufacturing and expands commercialization globally.
Operational Excellence: Whether the company can sustain this level of operational excellence amid increasing customer base and global expansion.
Market Positioning: The pace at which QT Imaging can leverage this regulatory milestone to strengthen its market position in the medical imaging sector.